Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine. (11th June 2013)

• Record Type: Journal Article
• Authors: Radke, Peter W.
• Other Names: Giannitsis Evangelos Academic Editor.; Hamm Christian Academic Editor.; Möckel Martin Academic Editor.; Searle Julia Academic Editor.
• Is Part Of: Conference papers in energy. Volume 2013(2013)
• Publication Date: 2013-06-11
• Subjects: Power resources -- Periodicals; Power resources; Periodicals; Electronic journals; 333.79
• DOI: 10.1155/2013/764619
• Languages: English
• ISSNs: 2314-582X

Abstract

Abstract : Antithrombin and antiplatelet therapies have been in the focus of pharmacological developments over recent years with an increasing number of anticoagulants and antiplatelets becoming available. While these drugs share common pharmacological characteristics (i.e., antiplatelet drugs binding to the P2Y12 receptor), they also differ substantially regarding metabolism, type of receptor binding, clinical end points that have been reduced as compared to the current gold standard, and, consequently, the spectrum of indication. These differences pose the need and, above that, great chances for therapy personalization. Understanding the challenges and opportunities that arise from the use of biological markers in guiding antiplatelet therapy is mandatory to provide best medical practice for patients with acute coronary syndromes.